The Motley Fool

A Practical Analysis Of GlaxoSmithKline plc’s Dividend

The ability to calculate the reliability of dividends is absolutely crucial for investors, not only for evaluating the income generated from your portfolio, but also to avoid a share-price collapse from stocks where payouts are slashed.

There are a variety of ways to judge future dividends, and today I am looking at GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) to see whether the firm looks a safe bet to produce dependable payouts.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Forward dividend cover

Forward dividend cover is one of the most simple ways to evaluate future payouts, as the ratio reveals how many times the projected dividend per share is covered by earnings per share. It can be calculated using the following formula:

Forward earnings per share ÷ forward dividend per share

GlaxoSmithKline is anticipated to provide a dividend of 74.5p per share in 2013, according to broker estimates, with earnings per share for this period forecast to come in at 116.2p. This means that dividend cover works out at 1.6 times prospective earnings, below the widely-regarded security threshold of 2 times.

Free cash flow

Free cash flow is essentially how much cash has been generated after all costs and can often differ from reported profits. Theoretically, a company generating shedloads of cash is in a better position to reward stakeholders with plump dividends. The figure can be calculated by the following calculation:

Operating profit + depreciation & amortisation – tax – capital expenditure – working capital increase

The pharma giant registered free cash flow of £2.05bn in 2012. This was down more than 50% from £4.14bn in the prior 12-month period, with a significant fall in operating profit — to £7.38bn from £7.81bn — weighing on cash flow. An increase in capex costs, allied to the phasing of tax payments, also caused the heavy deterioration.

Financial gearing

This ratio is used to gauge the level debt a company carries. Simply put, the higher the amount, the more difficult it may be to generate lucrative dividends for shareholders. It can be calculated using

the following calculation:

Short- and long-term debts + pension liabilities – cash & cash equivalents

___________________________________________________________ x 100

Shareholder funds

GlaxoSmithKline’s gearing readout came out at 192% in 2012, leaping from 72% in the previous year. This was primarily due to net debts advancing to £14.04bn last year from £9bn in 2011, driven by ongoing legal action in the US and the purchase of its HGS division for £2bn. As well, cash and cash equivalents fell during the period, while shareholder funds also dipped in 2012.

Buybacks and other spare cash

Here I’m looking at the amount of cash recently spent on share buybacks, repayments of debt and other activities that suggest the company may in future have more cash to spend on dividends.

GlaxoSmithKline is currently engaged in an active share repurchase programme, and has pencilled in buybacks worth between £1bn and £2bn for the current year. This is down from £2.5bn purchased in 2012 but still represents a meaty sum.

Typical of all pharmaceutical operators, GlaxoSmithKline devotes huge amounts of capital to R&D — as well as bubbly work on the acquisition front — to develop a fruitful product pipeline.

This is a theme hastened by the problem of major product expirations in recent times which has damaged revenue growth. Thus capex outlay should continue heading northwards. The company is aiming to introduce 15 key products across the globe over the next three years, in a bid to ‘grow a diversified global business’ and ‘deliver more products of value’.

The prescription for prize dividends

I believe that this devotion to innovation and expansion should deliver increasingly-appetising earnings growth, a situation which should undergird solid dividend expansion. The company boasts a stellar record of increasing full-year payouts even in times of earnings pressure, and I fully expect payments to roll relentlessly higher looking ahead.

And for the current year, the firm is ready to produce a dividend yield of 4.4% in 2013, if City estimates prove correct. This signals a very decent return compared with the FTSE 100 average of 3.3%.

The inside track to hot stocks growth

If you already hold shares in GlaxoSmithKline and are looking to significantly boost your investment returns elsewhere, check out this special Fool report, which outlines the steps you might wish to take in order to become a market millionaire.

Our “Ten Steps To Making A Million In The Market” report highlights how fast-growth small-caps and beaten-down bargains are all fertile candidates to produce ten-fold returns. Click here to enjoy this exclusive ‘wealth report’ — it’s 100% free and comes with no obligation.

> Royston does not own shares in GlaxoSmithKline.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US $12.3 TRILLION out of thin air…

And if you click here, we’ll show you something that could be key to unlocking 5G’s full potential...

It’s just ONE innovation from a little-known US company that has quietly spent years preparing for this exact moment…

But you need to get in before the crowd catches onto this ‘sleeping giant’.

Click here to learn more.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.